Enitociclib

Synonyms: (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib
Enitociclib((+)-BAY-1251152;(+) -VIP152)是一种选择性 CDK9 抑制剂(IC50=3 nM),通过阻断 RNA 聚合酶 II 的 Ser2/Ser5 磷酸化来抑制转录延伸,进而特异性耗竭 c-MYC、MCL-1 等关键短寿命蛋白并诱导肿瘤细胞凋亡(apoptosis),同时还干扰增强子 RNA(eRNA)的产生及增强子-启动子相互作用,从表观遗传层面下调致癌基因表达,并与 Bortezomib(MS-D47138)、Lenalidomide(MS-O60836)、Pomalidomide(MS-Q68284)、Venetoclax(MS-S50888)和 Paclitaxel等具有协同作用,甚至能逆转紫杉醇耐药性,是双打击弥漫性大 B 细胞淋巴瘤、多发性骨髓瘤及胰腺导管腺癌等多种恶性肿瘤的重要研究工具。
产品编号: MS-W53589 纯度: 99.89% CAS No.: 1610408-97-3 分子式: C19H18F2N4O2S 分子量: 404.43
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
2mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Enitociclib((+)-BAY-1251152;(+) -VIP152)是一种选择性 CDK9 抑制剂(IC50=3 nM),通过阻断 RNA 聚合酶 II 的 Ser2/Ser5 磷酸化来抑制转录延伸,进而特异性耗竭 c-MYC、MCL-1 等关键短寿命蛋白并诱导肿瘤细胞凋亡(apoptosis),同时还干扰增强子 RNA(eRNA)的产生及增强子-启动子相互作用,从表观遗传层面下调致癌基因表达,并与 Bortezomib(MS-D47138)、Lenalidomide(MS-O60836)、Pomalidomide(MS-Q68284)、Venetoclax(MS-S50888)和 Paclitaxel等具有协同作用,甚至能逆转紫杉醇耐药性,是双打击弥漫性大 B 细胞淋巴瘤、多发性骨髓瘤及胰腺导管腺癌等多种恶性肿瘤的重要研究工具。

生物实验数据

生物活性 Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II, thereby specifically depleting key short-lived proteins such as c-MYC and MCL-1 and inducing apoptosis in tumor cells; it also interferes with enhancer RNA (eRNA) production and enhancer-promoter interactions to downregulate oncogene expression at the epigenetic level, and exhibits synergistic effects with Bortezomib (MS-D47138), Lenalidomide (MS-O60836), Pomalidomide (MS-Q68284), Venetoclax (MS-S50888), and Paclitaxel, even reversing paclitaxel resistance, making it an important research tool for various malignancies including double-hit diffuse large B-cell lymphoma, multiple myeloma, and pancreatic ductal adenocarcinoma.
IC50 & Target

RNA Polymerase

 

CDK9/CycT1

3 nM (IC50)

体外研究
(In Vitro)

Enitociclib 可有效降低一组人类淋巴瘤细胞系的活力,其中包括 DLBCL 细胞系 SU-DHL-4 (IC50=43 nmol/L) 和 SU-DHL-10 (IC50=74 nmol/L)。
Enitociclib (0.25-1 μM; 4 h) 可在 SU-DHL-4 和 SU-DHL-10 DLBCL 细胞系中诱导以显著下调为主的转录组变化,包括新型靶点 PHF23 和 TP53RK 的显著下调,以及 RNA 聚合酶 II 介导的转录通路的富集。
Enitociclib (0.6-800 nM; 6-48 h) 可强效抑制原发性套细胞淋巴瘤 (MCL) 细胞、MCL 细胞系以及弥漫性大 B 细胞淋巴瘤 (DLBCL) 细胞系的活力,并诱导其发生 caspase-3 依赖性凋亡,IC50 为 11.5-172.3 nM。
Enitociclib (12.5-200 nM; 96 h) 可显著降低 MM1.S、NCI-H929、OPM-2 和 U266B1 多发性骨髓瘤细胞系的细胞活力,处理 96 小时后的 IC50 为 36 至 78 nM。
Enitociclib (0.5-1 μM; 1-24 h) 可通过剂量和时间依赖性地抑制 RNA Pol II CTD 在 Ser2/Ser5 位点的磷酸化,诱导 NCI-H929 和 OPM-2 多发性骨髓瘤细胞系发生凋亡并抑制癌蛋白的表达。
Enitociclib (25-500 nM; combined with paclitaxel) 可与紫杉醇协同抑制紫杉醇耐药性 L3.6pl 胰腺癌细胞的生长。

Western Blot Analysis

Cell Line: SU-DHL-4, SU-DHL-10 (DLBCL) cell lines
Concentration: 0.25 μmol/L; 1 μmol/L
Incubation Time: 4 h (treatment); up to 48 h post-washout (SU-DHL-4); up to 24 h post-washout (SU-DHL-10)
Result: Decreased p-Ser2 levels by 50% for up to 48 hours post-washout in SU-DHL-4 cells treated with 0.25 μmol/L.
Caused a greater extent of p-Ser2 inhibition that sustained for 48 hours post-washout in SU-DHL-4 cells treated with 1 μmol/L.
Achieved a 50% reduction of p-Ser2 for up to 24 hours post-washout in SU-DHL-10 cells treated with 1 μmol/L.

Real Time qPCR

Cell Line: SU-DHL-4, SU-DHL-10 (DLBCL) cell lines
Concentration: 0.25 μmol/L; 1 μmol/L
Incubation Time: 4 h (treatment); up to 48 h post-washout
Result: Inhibited MYC and MCL1 mRNA levels by approximately 75% for 16 to 48 hours post-washout in SU-DHL-10 cells.
Maintained durable depletion of MYC and MCL1 mRNA levels over the 48-hour time course in SU-DHL-4 cells treated with 1 μmol/L.

Cell Viability Assay

Cell Line: MM1.S, NCI-H929, OPM-2, U266B1 multiple myeloma cell lines
Concentration: 12.5-50 nM (in combination with other agents)
Incubation Time: 96 h
Result: Exhibited synergistic effects (ZIP synergy score >10) with bortezomib in OPM-2 cells at 50 nM enitociclib and 1 nM bortezomib.
Showed synergistic effects with lenalidomide in MM1.S, NCI-H929, and U266B1 cells at 12.5 to 25 nM enitociclib and 313 nM to 5 μM lenalidomide.
Demonstrated synergistic effects with pomalidomide in NCI-H929 and U266B1 cells at 12.5 nM enitociclib and 12.5 to 50 nM pomalidomide.
体内研究
(In Vivo)

Enitociclib (5-15 mg/kg;静脉注射;单剂量/每周 1 次;持续 3 周) 在 SU-DHL-10 DLBCL 异种移植模型中呈现剂量依赖性抗肿瘤功效,其中 15 mg/kg 每周 1 次的给药方案可诱导肿瘤完全消退,且所有测试剂量均能产生药效学效应,包括降低 p-Ser2 水平、下调 MYC/MCL1 表达,以及激活细胞凋亡。
Enitociclib (10 mg/kg;静脉注射;每周 2 次) 可强效抑制 NSG 小鼠中 JeKo-1 套细胞淋巴瘤 (MCL) 细胞系来源异种移植物的肿瘤生长并延长其生存期,且无明显毒性。
Enitociclib (15 mg/kg;静脉注射;每周 1 次) 可显著减小 SCID/Beige 小鼠体内 JJN-3 多发性骨髓瘤的肿瘤体积,单次给药 (15 mg/kg;静脉注射) 可短暂抑制癌基因转录并诱导肿瘤细胞凋亡。
Enitociclib (15 mg/kg;静脉注射;每周 1 次) 可显著降低 NOD/SCID 小鼠体内 OPM-2 多发性骨髓瘤的肿瘤体积,且与 Bortezomib (MS-D47138) 或 Lenalidomide (MS-O60836) 联用时疗效增强。
Enitociclib (10 mg/kg;静脉注射;每周 1 次;持续 4 周) 单药使用不会缩小肿瘤体积,但与 Paclitaxel (HY-B0015) 联用时,可在 Paclitaxel 耐药的胰腺癌患者来源异种移植模型中诱导显著的肿瘤缩小。

Animal Model: C.B-17 SCID (female, 10-12 weeks old at study start)
Dosage: 5 mg/kg (mechanistic single dose); 10 mg/kg (i.v. once weekly for 3 weeks; mechanistic single dose); 15 mg/kg (i.v. once weekly for 3 weeks; mechanistic single dose)
Administration: i.v.; single dose (mechanistic studies); once weekly; 3 weeks (antitumor efficacy)
Result: Achieved a tumor growth inhibition (T/C) value of 0.19 on day 16/20, with sustained tumor growth control at 10 mg/kg once weekly.
Induced complete tumor regression during the 3-week treatment period, with a T/C value of 0.005 on day 16/20 at 15 mg/kg once weekly; tumors regrew after treatment cessation, but a second cycle of 15 mg/kg once weekly dosing induced tumor regression again.
Reduced RNA polymerase II Ser2 phosphorylation (p-Ser2) by >50% for 8 hours postdose; depleted MYC and MCL1 mRNA levels by 4 hours postdose, with depletion sustained for 8 hours at 5 mg/kg single dose.
Depleted p-Ser2 levels within 8 hours postdose; depleted MYC and MCL1 mRNA levels by 4 hours postdose, with depletion sustained for 8 hours; reduced Myc protein levels by 50% and Mcl-1 protein levels robustly within 4-8 hours postdose; increased cleaved PARP (apoptosis marker) levels postdose at 10 mg/kg and 15 mg/kg single dose.
Animal Model: NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (immunodeficient)
Dosage: 10 mg/kg
Administration: i.v.; twice a week
Result: Markedly inhibited tumor growth.
Significantly prolonged mouse survival.
Caused no significant body weight loss or other apparent adverse effects.\nEfficaciously inhibited PDX-1 tumor growth.
Caused no significant body weight loss.\nEfficaciously inhibited PDX-2 tumor growth.
Caused no significant body weight loss.\nEfficaciously inhibited PDX-3 tumor growth.
Caused no significant body weight loss.
Animal Model: NOD/SCID (gender not specified; injected subcutaneously with 5.0×106 OPM-2 MM cells)
Dosage: 15 mg/kg (monotherapy); 15 mg/kg (in combination with lenalidomide or bortezomib)
Administration: i.v.; once per week
Result: Significantly reduced OPM-2 tumor volumes compared with vehicle-treated mice as monotherapy.
Further enhanced antitumor efficacy compared with lenalidomide or bortezomib alone when combined with 50 mg/kg Lenalidomide (p.o.
daily) or 0.8 mg/kg Bortezomib (i.p.
twice weekly).
性状 固体
颜色 Off-white to yellow

化学信息

分子量 404.43
分子式 C19H18F2N4O2S
CAS No. 1610408-97-3
别名 (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 113.3 mg/mL (280.15 mM; 超声加热助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.4726 mL12.3631 mL24.7262 mL61.8154 mL
5 mM0.4945 mL2.4726 mL4.9452 mL12.3631 mL
10 mM0.2473 mL1.2363 mL2.4726 mL6.1815 mL
15 mM0.1648 mL0.8242 mL1.6484 mL4.1210 mL
20 mM0.1236 mL0.6182 mL1.2363 mL3.0908 mL
25 mM0.0989 mL0.4945 mL0.9890 mL2.4726 mL
30 mM0.0824 mL0.4121 mL0.8242 mL2.0605 mL
40 mM0.0618 mL0.3091 mL0.6182 mL1.5454 mL
50 mM0.0495 mL0.2473 mL0.4945 mL1.2363 mL
60 mM0.0412 mL0.2061 mL0.4121 mL1.0303 mL
80 mM0.0309 mL0.1545 mL0.3091 mL0.7727 mL
100 mM0.0247 mL0.1236 mL0.2473 mL0.6182 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础